We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Surge Expected in Personal Flow Cytometry Market

By LabMedica International staff writers
Posted on 17 Feb 2011
The use of flow cytometers in biotech research laboratories should get a boost after the acquisition of a pioneer manufacturer of personal flow cytometers by one of the major international medical technology companies.

Flow cytometry is a method of sorting and measuring types of cells by fluorescent labeling of markers on the surface of the cells. More...
Accuri Cytometers, Inc. (Ann Arbor, MI, USA) was founded to address a compelling need: life scientists love the rapid cell-by-cell analysis capability of flow cytometers, but too few have a flow cytometer in their laboratory. The barriers for most researchers include cost of the instrument, complexity of the software, effort required for maintenance, and the large amount of bench space required for the instrument.

Accuri Cytometers developed the C6, a system so easy to operate and maintain that a dedicated operator is not required. New C6 users can be trained in less than 30 minutes. The C6 employs laboratory-grade water for sheath fluid so commercial sheath fluids are not needed. Maintenance is made simple with automatic rinse and decontamination upon instrument shutdown. No room renovations are required to install a C6, since it fits easily on the benchtop and uses standard electrical connections. The C6 is small enough to fit into every lab and can even be placed in a laminar flow hood

To secure a firm place at the head of the flow cytometry parade, Becton, Dickinson and Company (BD) (Franklin Lakes, NJ, USA) has acquired Accuri Cytometers. BD is a global medical technology company that is focused on improving drug delivery, enhancing the diagnosis of infectious diseases and cancers, and advancing drug discovery. BD develops, manufactures, and sells medical supplies, devices, laboratory instruments, antibodies, reagents, and diagnostic products. It serves healthcare institutions, life science researchers, clinical laboratories, and the pharmaceutical industry.

The acquisition is subject to regulatory approvals and is expected to close during the third quarter of fiscal year 2011.

"Making flow cytometry more accessible to a wider audience of scientists and clinicians is one aspect of our cell analysis growth strategy,” said William Rhodes, president of BD Biosciences. "With its small footprint, ease of use and affordable price, the Accuri flow cytometer enables the adoption of flow cytometry by a broad range of researchers whom BD does not currently serve.”

Related Links:
Accuri Cytometers, Inc.
Becton, Dickinson and Company (BD)




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.